Seeking Alpha
View as an RSS Feed

Stan The Man  

View Stan The Man's Comments BY TICKER:

Latest  |  Highest rated
  • Should General Electric Shareholders Swap For Synchrony? [View article]
    I already have 2/3 in Roth and 1/3 in taxable IRA. Did my big exchange to Roth in 2008-9 at depressed prices...worked out well.
    Oct 27, 2015. 10:07 AM | 1 Like Like |Link to Comment
  • Cheniere does not expect to overtake Russia as Europe's top LNG player [View news story]
    Chenier. "Chenille" was courtesy of my computer's text editing program.
    Oct 27, 2015. 10:02 AM | 1 Like Like |Link to Comment
  • Cheniere does not expect to overtake Russia as Europe's top LNG player [View news story]
    So Chanos is always right and Icahn is always wrong?

    The economics remain to be shown, but the big picture is already clear. Chenille will have the field of US exports to itself for quite awhile.
    Oct 27, 2015. 10:01 AM | Likes Like |Link to Comment
  • Cheniere does not expect to overtake Russia as Europe's top LNG player [View news story]
    A dumb announcement, like what brand of soda drink Souki prefers with his lunch.

    Why should anybody care if Cheniere takes over the world, or is only #2, or #3 in Europe? If an article announced that Chevron does not expect to become the world's #1 supplier, would anybody be surprised, or care?
    Oct 26, 2015. 10:41 AM | Likes Like |Link to Comment
  • Should General Electric Shareholders Swap For Synchrony? [View article]
    I own all my stock in my IRA, so tax consequences are not relevant to me. I'm inclined to try the arbitrage with all my stock, and then buy back the GE.
    Oct 20, 2015. 10:37 AM | 4 Likes Like |Link to Comment
  • A Possible Cure For Blindness: The Ocata Preclinical Pipeline- Photoreceptor Progenitors [View article]
    Whatever happened to the program to develop a replacement blood product in conjunction with the military, which would end the need to get blood from live donors?
    Sep 30, 2015. 01:29 PM | 1 Like Like |Link to Comment
  • Organovo: Competition And Profit Potential [View article]
    See my comment above on Inspiro vs. ONVO
    Oct 7, 2014. 11:36 AM | 1 Like Like |Link to Comment
  • Organovo: Competition And Profit Potential [View article]
    Seems to me if Inspiro was so great vs. the ONVO product, Roche would not be trumpeting the results of its recent back checking work with ONVO.

    I don't pretend to know the details. But here's a thought. Lets assume both these products were backtested with a number of compounds that subsequently failed because of adverse liver toxicity. Hypothetically, if one product predicted liver toxicity in 75% of these compounds later found to have adverse liver toxicity, and the other product predicted liver toxicity in 90% of such compounds, would anyone care if the 90% predictor cost 10 times as much? Would anyone buy the 75% predictor product to save $100,000 at the risk of wasting $$millions on development work on this compound? That would be stupid.

    So if the ONVO product demonstrates superior liver toxicity predictability, it can command a hefty $$$ premium price. And if the Inspiro product is so good, why are they charging so little?
    Oct 7, 2014. 11:31 AM | 4 Likes Like |Link to Comment
  • Organovo: Competition And Profit Potential [View article]
    It looks to me like the liver product will "succeed" but its not going to make the company a giant moneymaker by itself, and it won't be adopted by everyone on day one. The point is that this will be a start, and a good one, and there are tons of opportunities for the company in the liver area as well as other areas.
    Sep 30, 2014. 12:20 AM | 3 Likes Like |Link to Comment
  • Organovo: Competition And Profit Potential [View article]
    Congrats on the article! I listened to the conference call and came away energized by the possibilities and the way the company is moving forward. I believe the text of the call is still available for anyone interested.

    The thrust of the message was that the technology works to make better (3D) tissues for drug development testing, and there is tremendous interest in this from big pharma. An interesting note was that there are generally few if any regulatory approvals needed for the company to market its products to pharma for drug development study. That's because the ONVO products are generally not used to prove the safety or efficacy of products, but rather to help big pharma screen their products for toxicity at an early stage and in a cost effective way. If a Roche or other big company learns early that a potential drug has adverse liver toxicity, it can save enormous amounts of money by not moving forward to formal testing of that product.

    ONVO is just at the beginning of commercializing its technology, but the results thus far have been excellent, and the potential upside is huge.
    Sep 29, 2014. 05:31 PM | 3 Likes Like |Link to Comment
  • Advanced Cell Technology And Dilution: Do We Really Have A Rational Choice? [View article]
    A vote for increasing authorized shares is not the same as voting for dilution. Having the shares authorized gives the company flexibility to use the shares but that doesn't mean they will use them. It just means they feel the need to keep their options open. And if they do use them, and use them wisely, existing shareholders will benefit.

    In my opinion, the constant harping about the risk of dilution is misplaced. Just like the previous and continuing harping about the supposed negative effects of a reverse stock split. This company has a continuing need to raise cash to fund future development -- just like any early stage biotech company which will probably not be generating revenues soon. Would anyone seriously quarrel with a scenario where (a) the Phase 1 results get published soon, (b) the stock shoots up to $30 or more, and (c) the company sells some shares at $30 to raise cash? That cash could presumably fund operations while the next steps are taken that could drive the stock higher. The concern would not be the sale of shares, per se, but the price and timing of any sale.

    The company will need to raise cash eventually, either through partnering or by selling shares, but hopefully they will wait until the stock price is much higher. In any case, they need to get this shareholder authorization. A negative vote would not be a plus for shareholders, it would just make it harder for the company to raise cash.
    Sep 29, 2014. 03:59 PM | 10 Likes Like |Link to Comment
  • A Repudiation Of Advanced Cell Technology's 'Whisper' Results [View article]
    Selling the rallies and buying the troughs works great when a stock trades in a channel. But stocks like this have been known to go up 400% in a day. Selling the first 20% gain makes you feel sick when the stock continues to go up while you are waiting for your next chance to buy at the bottom of the channel.

    Of course this pattern could persist and your strategy might work for you. But I think that strategy is best suited to trading a stock that is stuck in a range, not a stock that is awaiting events that could make it skyrocket.
    Sep 24, 2014. 10:40 AM | 2 Likes Like |Link to Comment
  • A Repudiation Of Advanced Cell Technology's 'Whisper' Results [View article]

    While I agree with some of the things you say, especially your critique of this article, your comment that the stock is "right back to where it should be" assumes you somehow have the insight to know this. I think that viewpoint is nonsense.

    When the stock gets to $50 on this upcoming article, what will it mean that you believed the "right price" pre-article was $7.92 instead of $9.00 or some different number? Precisely nothing.

    My average cost was also around $7.00 but I've been buying more on the way down since around $8.70. That doesn't mean I know what the "right price" should be, but it shows that I'm doing the only relevant thing, voting now with my dollars.

    Since the stock traded around these prices this summer, the company has (1) settled their lawsuit relating to prior financing, (2) settled with SEC regarding the previous President's stock sales, (3) received a patent to commercially produce stem cells which sounds like it might be important, (4) completed the reverse stock split previously approved, and which was a precondition to uplifting to NASDAQ, and (5) created a top notch Scientific Advisory Board, demonstrating these well regarded scientists are believers. And the peer-reviewed paper describing their AMD trials -- previously discussed by the company at the latest investor day as expected shortly -- is that much closer to being published.

    To me, those developments justify a higher valuation than was put on this during the summer. That's why I've been buying more.
    Sep 23, 2014. 03:47 PM | 4 Likes Like |Link to Comment
  • Report: Apple shutting down Beats Music (updated) [View news story]
    Regarding the 10 million number... (1) Does it include resales by ATT and other vendors or only represent direct sales by Apple, and (2) Has Apple announced how many more have been ordered that are awaiting delivery? I ordered an iPhone 6+ at ATT the first day and their estimated delivery date is still early November (!).
    Sep 22, 2014. 04:20 PM | Likes Like |Link to Comment
  • A Repudiation Of Advanced Cell Technology's 'Whisper' Results [View article]
    Here is the abstract of the paper from 2012 in Lancet (of a study funded by ACT)


    The Lancet, Volume 379, Issue 9817, Pages 713 - 720, 25 February 2012 <Previous Article|Next Article>
    doi:10.1016/S0140-6736... or Link Using DOI
    This article can be found in the following collections: Cardiology & Vascular Medicine (Cardiology & vascular-other)
    Published Online: 24 January 2012
    Copyright © 2012 Elsevier Ltd All rights reserved.
    Embryonic stem cell trials for macular degeneration: a preliminary report

    Prof Steven D Schwartz MD a Corresponding AuthorEmail Address, Jean-Pierre Hubschman MD a, Gad Heilwell MD a, Valentina Franco-Cardenas MD a, Carolyn K Pan MD a, Rosaleen M Ostrick MPH a, Edmund Mickunas MS b, Roger Gay PhD b, Irina Klimanskaya PhD b, Dr Robert Lanza MD b Corresponding AuthorEmail Address

    It has been 13 years since the discovery of human embryonic stem cells (hESCs). Our report provides the first description of hESC-derived cells transplanted into human patients.
    We started two prospective clinical studies to establish the safety and tolerability of subretinal transplantation of hESC-derived retinal pigment epithelium (RPE) in patients with Stargardt's macular dystrophy and dry age-related macular degeneration—the leading cause of blindness in the developed world. Preoperative and postoperative ophthalmic examinations included visual acuity, fluorescein angiography, optical coherence tomography, and visual field testing. These studies are registered with, numbers NCT01345006 and NCT01344993.
    Controlled hESC differentiation resulted in greater than 99% pure RPE. The cells displayed typical RPE behaviour and integrated into the host RPE layer forming mature quiescent monolayers after transplantation in animals. The stage of differentiation substantially affected attachment and survival of the cells in vitro after clinical formulation. Lightly pigmented cells attached and spread in a substantially greater proportion (>90%) than more darkly pigmented cells after culture. After surgery, structural evidence confirmed cells had attached and continued to persist during our study. We did not identify signs of hyperproliferation, abnormal growth, or immune mediated transplant rejection in either patient during the first 4 months. Although there is little agreement between investigators on visual endpoints in patients with low vision, it is encouraging that during the observation period neither patient lost vision. Best corrected visual acuity improved from hand motions to 20/800 (and improved from 0 to 5 letters on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual acuity chart) in the study eye of the patient with Stargardt's macular dystrophy, and vision also seemed to improve in the patient with dry age-related macular degeneration (from 21 ETDRS letters to 28).
    The hESC-derived RPE cells showed no signs of hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection after 4 months. The future therapeutic goal will be to treat patients earlier in the disease processes, potentially increasing the likelihood of photoreceptor and central visual rescue.
    Advanced Cell Technology.
    Sep 22, 2014. 12:10 PM | Likes Like |Link to Comment